CRISPR Therapeutics takes a swing at ALS gene editing in discovery deal with AAV upstart Capsida

When small biotech Capsida launched just a few months ago, it hit the scene with backing from drug giant AbbVie to chase AAV-delivered drugs for CNS. Now, the team has earned the support of one of the biggest names in gene editing — and it’s taking on a big challenge right away.